We observed that NPM1-mutated AML patients had favorable responses to azacitidine/venetoclax, with a trend towards higher rates of MRD negative response at 0.1% sensitivity (64% versus 33%) and a 12-month OS of 72% versus 57% in patients without NPM1 mutated AML. Here, NPM1 is linked to acute myeloid leukemia.